Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells

A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways

(2018) Dayun Yang et al.   JOURNAL OF CONTROLLED RELEASE

Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways

(2018) Xiaolan Lian et al.   Journal of Hematology & Oncology

A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action

(2017) Elena Campaner et al.   Nature Communications

ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5

(2016) Hui-Lung Sun et al.   CANCER CELL

The Roles of the Unique Prolyl Isomerase Pin1 in Cancer-Related Viral and Bacterial Infections

(2016) J. Wang et al.   CURRENT MOLECULAR MEDICINE

Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc

(2016) Luana D’Artista et al.   Oncotarget

Pin1-Targeted Therapy for Systemic Lupus Erythematosus

(2016) Shuo Wei et al.   Arthritis & Rheumatology

Global Analysis of Protein Expression and Phosphorylation Levels in Nicotine-Treated Pancreatic Stellate Cells

(2015) Joao A. Paulo et al.   JOURNAL OF PROTEOME RESEARCH

Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy

(2015) Asami Kondo et al.   NATURE

Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer

(2015) Shuo Wei et al.   NATURE MEDICINE

Epidemiology of chronic disease related to arsenic in Argentina: A systematic review

(2015) Ariel Esteban Bardach et al.   SCIENCE OF THE TOTAL ENVIRONMENT

The Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis via Erk Signaling Activation

(2015) Man-Li Luo et al.   Cell Reports

Prolyl isomerase Pin1 in cancer

(2014) Zhimin Lu et al.   CELL RESEARCH

Rapid Reduction in Breast Cancer Mortality With Inorganic Arsenic in Drinking Water

(2014) Allan H. Smith et al.   EBioMedicine

Pin1 inhibitors: Pitfalls, progress and cellular pharmacology

(2013) Jonathan D. Moore et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Arsenic Binding to Proteins

(2013) Shengwen Shen et al.   CHEMICAL REVIEWS

Molecular Pathways: Current Role and Future Directions of the Retinoic Acid Pathway in Cancer Prevention and Treatment

(2013) R. M. Connolly et al.   CLINICAL CANCER RESEARCH

Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast

(2013) Alessandra Rustighi et al.   EMBO Molecular Medicine

Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia

(2013) Guilherme Augusto dos Santos et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies

(2013) Julien Ablain et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Pin1 Regulates the Dynamics of c-Myc DNA Binding To Facilitate Target Gene Regulation and Oncogenesis

(2013) A. S. Farrell et al.   MOLECULAR AND CELLULAR BIOLOGY

DNA targeting specificity of RNA-guided Cas9 nucleases

(2013) Patrick D Hsu et al.   NATURE BIOTECHNOLOGY

Proline Isomer-Specific Antibodies Reveal the Early Pathogenic Tau Conformation in Alzheimer's Disease

(2012) Kazuhiro Nakamura et al.   CELL

Arsenic compounds: revived ancient remedies in the fight against human malignancies

(2012) Jian-Xiang Liu et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Negative Regulation of the Stability and Tumor Suppressor Function of Fbw7 by the Pin1 Prolyl Isomerase

(2012) Sang-Hyun Min et al.   MOLECULAR CELL

A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer

(2011) Javier E. Girardini et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Integration, scaling, space-group assignment and post-refinement

(2010) Wolfgang Kabsch   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3

(2010) Marion Jeanne et al.   CANCER CELL

Randomized Phase II Trial of All-Trans-Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-Line Treatment in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Oscar Arrieta et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Retinoic acid regulates bone morphogenic protein signal duration by promoting the degradation of phosphorylated Smad1

(2010) N. Sheng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Arsenic Trioxide Controls the Fate of the PML-RAR  Oncoprotein by Directly Binding PML

(2010) X. W. Zhang et al.   SCIENCE

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

Pin1 Down-regulates Transforming Growth Factor-β (TGF-β) Signaling by Inducing Degradation of Smad Proteins

(2009) Ayako Nakano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation

(2009) Y Liao et al.   ONCOGENE

Acute promyelocytic leukemia: from highly fatal to highly curable

(2008) Z.-Y. Wang et al.   BLOOD

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

(2008) Rihab Nasr et al.   NATURE MEDICINE

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

(2007) E. Fox et al.   BLOOD